CHMP5 and viral infectious disease: Therefore, we hypothesize that a replication-competent, Spike-pseudotyped VSV-based vaccine platform would be more successful if administered IN because (1) ACE2 is expressed at high levels in the nasal mucosa and (2) the local intranasal induction of anti-Spike immune responses may be more effective in preventing an initial viral infection than an intramuscular vaccination.